SELLAS Life Sciences (SLS) Net Cash Flow (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Net Cash Flow of $35.4 million for Q1 2026, up 143.61% year-over-year from $14.5 million in Q1 2025, and up 28.72% quarter-over-quarter from $27.5 million in Q4 2025.
SELLAS Life Sciences (SLS) Net Cash Flow (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Net Cash Flow for 17 consecutive years, with $35.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 143.61% year-over-year to $35.4 million; the TTM figure through Mar 2026 stood at $78.7 million (up 688.77% YoY), while the FY2025 annual figure was $57.9 million, up 409.83% from the prior year.
- Net Cash Flow advanced to $35.4 million in Q1 2026 per SLS's latest filing, from $27.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $35.4 million in Q1 2026 and bottomed at -$9.8 million in Q3 2023.
- Historically, Net Cash Flow has averaged $5.5 million across 5 years, with a median of -$1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 814.81% — and 2024, when it plunged 396.53%.
- SELLAS Life Sciences' Net Cash Flow stood at -$4.2 million in 2022, then jumped by 65.92% to -$1.4 million in 2023, then tumbled by 396.53% to -$7.1 million in 2024, then jumped by 484.35% to $27.5 million in 2025, then rose by 28.72% to $35.4 million in 2026.
- Business Quant data shows SLS's Net Cash Flow at $35.4 million in Q1 2026, $27.5 million in Q4 2025, and $19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 31.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.25 Mn |
| Jun 30, 2026 | 31.25 Mn |
| Mar 31, 2026 | 35.35 Mn |
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 27.46 Mn |
| Dec 31, 2025 | 27.46 Mn |
| Sep 30, 2025 | 19.02 Mn |
| Sep 30, 2025 | 19.02 Mn |
| Jun 30, 2025 | -3.10 Mn |
| Jun 30, 2025 | -3.10 Mn |
| Mar 31, 2025 | 14.51 Mn |
| Mar 31, 2025 | 14.51 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Sep 30, 2024 | 11.88 Mn |
| Jun 30, 2024 | -9.27 Mn |
| Jun 30, 2024 | -9.27 Mn |
| Mar 31, 2024 | 15.89 Mn |
| Mar 31, 2024 | 15.89 Mn |